Rosiglitazone safety update

Ongoing controversy over the safety of rosiglitazone (Avandia) has prompted the MHRA to reissue its advice on minimising the drug's cardiovascular impact.

Over 1 million prescriptions for Avandia were written in the UK in 2009
Over 1 million prescriptions for Avandia were written in the UK in 2009

The agency reminds healthcare professionals that rosiglitazone:

  • Must not be used in patients with heart failure, history of heart failure, or acute coronary syndrome.
  • Is not recommended in patients with ischaemic heart disease or peripheral arterial disease.
  • Should be used with insulin only in exceptional circumstances and under close supervision.

Patients being treated with rosiglitazone should be monitored for signs of fluid retention, including weight gain and cardiac failure. Treatment should be discontinued if cardiac status deteriorates.

The debate over rosiglitazone’s adverse cardiovascular effects has been fuelled by recent publications, including a retrospective cohort study and a meta-analysis of randomised controlled trials, pointing towards an increased risk of myocardial infarction and other cardiovascular events for rosiglitazone compared with both placebo and pioglitazone.

Updated 24 September 2010

Avandia and Avandamet marketing authorisations suspended

 

On 23 September 2010, the European Medicines Agency recommended the suspension of marketing authorisation for rosiglitazone-containing drugs.

 

Click this link for full story

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.